A September 2026 study in the journal Obesity found that 35.1% of adults prescribed a GLP-1 without a documented FDA-qualifying indication had a normal BMI
The study looked at data from Epic Cosmos electronic health records, which is representative of more than 300 million patients across the U.S. as of January 2026.
Some points:
35.1% had a normal BMI at the time of the prescription.
Median BMI was 25.9, compared with 24.5 among adults in the same pool who did not receive a GLP
85.5% were women and 60% were White; 78% had private insurance.
A documented eating-disorder history was six times more common (1.8% versus 0.3%).
Drugs were liraglutide, semaglutide, and tirzepatide, identified by ingredient, not brand.